Table 2. 0.4% oxybuprocaine induced corneal anesthesia in rats and effect of pentadecapeptide BPC 157 (0.4 µg/eye), L-NAME (0.1 mg/eye) and/or L-arginine (2 mg/eye) administered alone and in combination after complete corneal anesthesia was established, at 1 min after 0.4% oxybuprocaine.

Pentadecapeptide BPC 157 (0.4 µg/eye), L-NAME (0.1 mg/eye), L-arginine (2 mg/eye), administered alone and in combination after complete corneal anesthesia was established, at 1 min after 0.4% oxybuprocaine corneal anesthesia	Duration of 0.4% oxybuprocaine corneal anesthesia
	T1 (min), mean ± SD	T4 (min), mean ± SD
Saline	64±5.7	126±3.9
BPC 157	51±5.0*	106±7.4*
L-arginine	56±6.9*	112±5.9*
L-arginine + BPC 157	48±5.9*#	96±5.5*#
L-NAME	89±5.7*	137±7.9*
L-NAME + BPC 157	71±7.6#	104±7.0*#
L-arginine + L-NAME	77±6.7*+	131±8.0
L-arginine + L-NAME + BPC 157	60±7.2#	98±6.7*#

T1 = time point when blink response to maximal corneal stimulation appeared again; T4 = time point when corneal sensitivity returned to baseline values; T1-T4 = complete corneal anesthesia duration (minutes, mean ± SD); *p<0.05 vs. saline (control); ^#p<0.05 vs. corresponding ‘non-BPC 157 group’; ⁺p<0.05 vs. corresponding ‘L-NAME-group’; Mann-Whitney test for independent samples followed by Benjamini and Hochberg procedure to control the false discovery rate (FDR)